ee

Registreeru
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele.

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・BioNTech SE ADR
Search

BioNTech SE ADR

Suletud

Sektor Tervishoid

89.58 -0.49

Osta

Hinna uuendus 6. sept 2024, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

88.71

Max

90.18

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+20.24 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2024

Uudiste sentiment

By Acuity

50%

50%

114 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

88.19 / 90.24 Toetus ja vastupanu

BioNTech SE ADR Graafik

Seotud uudised

6. mai 2024, 11:27 UTC

Tulu

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

DJ

Loe

20. märts 2024, 10:44 UTC

Tulu

BioNTech Profit Slumps on Lower Covid Vaccine Sales

DJ

Loe

8. veebr 2024, 11:43 UTC

Omandamised, ülevõtmised, äriostud

BioNTech Agrees To Invest $200 Million in Autolus, Starts Strategic Collaboration

DJ

Loe

5. aug 2024, 10:02 UTC

Tulu

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

DJ

Loe

5. aug 2024, 10:01 UTC

Tulu

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

DJ

Loe

5. aug 2024, 10:01 UTC

Tulu

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

DJ

Loe

5. aug 2024, 10:00 UTC

Tulu

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

DJ

Loe

5. aug 2024, 09:59 UTC

Tulu

BioNTech 2Q Loss EUR807.8M >BNTX

DJ

Loe

5. aug 2024, 09:59 UTC

Tulu

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

DJ

Loe

5. aug 2024, 09:59 UTC

Tulu

BioNTech 2Q Rev EUR128.7M >BNTX

DJ

Loe

6. mai 2024, 20:15 UTC

Tulu

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

DJ

Loe

6. mai 2024, 10:47 UTC

Tulu

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

DJ

Loe

6. mai 2024, 10:46 UTC

Tulu

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

DJ

Loe

6. mai 2024, 10:46 UTC

Tulu

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

DJ

Loe

6. mai 2024, 10:46 UTC

Tulu

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

DJ

Loe

6. mai 2024, 10:45 UTC

Tulu

BioNTech 1Q Rev $187.6M >BNTX

DJ

Loe

6. mai 2024, 10:45 UTC

Tulu

BioNTech 1Q Loss $315.1M >BNTX

DJ

Loe

6. mai 2024, 10:45 UTC

Tulu

BioNTech 1Q Loss/Shr $1.31 >BNTX

DJ

Loe

26. märts 2024, 05:00 UTC

Tulu

This Vaccine Maker Sits on Cash Almost Equal to Its Market Value -- Barrons.com

DJ

Loe

20. märts 2024, 11:44 UTC

Tulu

BioNTech Earnings Fall Short of Estimates. The Stock Is Down. -- Barrons.com

DJ

Loe

20. märts 2024, 10:27 UTC

Tulu

BioNTech's Stock Sinks After Earnings Fall Below Expectations, Hurt By Writedowns Of Vaccine Inventory -- MarketWatch

DJ

Loe

20. märts 2024, 10:17 UTC

Tulu

BioNTech 4Q Rev EUR1.48B >BNTX

DJ

Loe

20. märts 2024, 10:15 UTC

Tulu

Biontech 4Q Net Pft EUR457.9M

DJ

Loe

20. märts 2024, 10:15 UTC

Tulu

Biontech Plans For Ten or More Registrational Oncology Trials By End of 2024

DJ

Loe

20. märts 2024, 10:15 UTC

Tulu

Biontech: Annemarie Hanekamp appointed to Management Board as Chief Commercial Officer, effective Jul. 1

DJ

Loe

20. märts 2024, 10:15 UTC

Tulu

Biontech Aims For First Oncology Launch in 2026 and Ten Indication Approvals by 2030

DJ

Loe

20. märts 2024, 10:15 UTC

Tulu

Biontech 2023 Gross Profit For COVID-19 Vaccine Business EUR3.2B

DJ

Loe

20. märts 2024, 10:15 UTC

Tulu

Biontech Sees 2024 Revenue Between EUR2.5B - EUR3.1B

DJ

Loe

20. märts 2024, 10:15 UTC

Tulu

Biontech 4Q Rev EUR1.48B

DJ

Loe

8. veebr 2024, 11:28 UTC

Omandamised, ülevõtmised, äriostud

BioNTech Agrees To Invest $200 Mln in Autolus, Starts Strategic Collaboration

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

BioNTech SE ADR Prognoos

Hinnasiht

By TipRanks

20.24% tõus

12 kuu keskmine prognoos

Keskmine 108.4 USD  20.24%

Kõrge 171 USD

Madal 85 USD

Põhineb 13 Wall Streeti analüütiku instrumendi BioNTech SE ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

6

Osta

6

Hoia

1

Müü

Põhineb 13 analüütiku instrumendi BioNTech SE ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

88.19 / 90.24Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

All events are bullish.

Keskpikk perspektiiv

Bullish Evidence

Recent bullish events outweigh bearish events.

Pikk perspektiiv

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

114 / 365 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

902.74

↓-0.9%

UNH

UnitedHealth Group Inc

596.8

↑ +0.31%

NVO

Novo Nordisk A-S

131.05

↑ +0.18%

JNJ

Johnson and Johnson

164.37

↓-0.29%

ABBV

AbbVie Inc

193.18

↑ +0.34%